371 related articles for article (PubMed ID: 19947894)
1. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
[TBL] [Abstract][Full Text] [Related]
2. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP
Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Tiwari A
Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Forst T; Pfützner A
Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Grunberger G
Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
Med Lett Drugs Ther; 2011 Jun; 53(1367):49-50. PubMed ID: 21701440
[No Abstract] [Full Text] [Related]
9. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Scheen AJ
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
[TBL] [Abstract][Full Text] [Related]
12. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
Friedrich C; Emser A; Woerle HJ; Graefe-Mody U
Am J Ther; 2013; 20(6):618-21. PubMed ID: 23411609
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):363-77. PubMed ID: 23373842
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
Neumiller JJ
Ann Pharmacother; 2012 Mar; 46(3):358-67. PubMed ID: 22318932
[TBL] [Abstract][Full Text] [Related]
16. [Oral Linagliptin (Trajenta)].
Duh D; Tanret I
J Pharm Belg; 2013 Mar; (1):41-3. PubMed ID: 23638612
[No Abstract] [Full Text] [Related]
17. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
Ohmura T; Hayashi N; Encinas J
Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
[No Abstract] [Full Text] [Related]
[Next] [New Search]